A prognostic risk model for the occurrence of serious adverse events in breast cancer patients on Adriamycin-based chemotherapy.

The records of breast cancer patients undergoing Adriamycin-based therapy at the medical oncology dept will be assessed for the occurrence of serious adverse events (SAEs). The patient’s demographic and baseline data will be recorded by a pre-formed questionnaire. Predictor risk factors will be analysed for the occurrence of SAEs. All the potential risk factors for causing SAEs will be noted and considered for construction and validation of nomogram.